Search Results - "Luen, Stephen James"
-
1
Evaluation of PAM50 intrinsic subtypes and risk of recurrence (ROR) scores in premenopausal women with early-stage HR+ breast cancer: A secondary analysis of the SOFT trial
Published in Journal of clinical oncology (01-06-2023)“…504 Background: The landmark Suppression of Ovarian Function Trial (SOFT) in premenopausal breast cancer patients revealed that the addition of ovarian…”
Get full text
Journal Article -
2
Comparing survival outcomes for advanced cancer patients who access comprehensive genomic sequencing using a registry-based synthetic control arm
Published in Journal of clinical oncology (20-05-2021)“…Abstract only e18851 Background: Studies evaluating the clinical benefit from Comprehensive Genomic Sequencing (CGS) in cancer patients (pts) have been limited…”
Get full text
Journal Article -
3
Abstract P1-18-14: Alpelisib monotherapy for PI3K-altered, pre-treated advanced breast cancer: A phase II study
Published in Cancer research (Chicago, Ill.) (15-02-2022)“…Abstract Background: The PI3Kα subunit specific inhibitor alpelisib in combination with fulvestrant is approved in advanced breast cancer harbouring PIK3CA…”
Get full text
Journal Article -
4
A Malignant Neoplasm From the Jejunum With a MALAT1-GLI1 Fusion and 26-Year Survival History
Published in International journal of surgical pathology (01-08-2020)“…The transcription factor GLI1 is a critical effector of the sonic hedgehog pathway. Gene fusions that activate GLI1 have recently been reported in several…”
Get full text
Journal Article -
5
Plasma and tumor genomic correlates of response to BYL719 in PI3KCA mutated metastatic ER-positive breast cancer (ER+/HER2- BC)
Published in Journal of clinical oncology (20-05-2018)“…Abstract only…”
Get full text
Journal Article -
6
On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome
Published in Journal of clinical oncology (20-05-2019)“…Abstract only 574 Background: Higher quantity of pretreatment TIL (PT) is associated with improved pCR and EFS in HER2+ early breast cancer (BC). The value of…”
Get full text
Journal Article -
7
Prognostic implications of residual disease (RD) tumor-infiltrating lymphocytes (TIL) in triple negative breast cancer (TNBC) after neo-adjuvant chemotherapy (NAC)
Published in Journal of clinical oncology (20-05-2018)“…Abstract only…”
Get full text
Journal Article -
8
Retrospective review of the impact of a dedicated Cancer of Unknown Primary (CUP) clinic
Published in Journal of clinical oncology (20-05-2015)“…Abstract only…”
Get full text
Journal Article